Patient-Reported Outcomes for Migraine in the US and Europe: Burden Associated with Multiple Preventive Treatment Failures

References

• Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd ed. Cephalalgia. 2018;38(1):1–211. doi:10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Lampl C, Thomas H, Stovner LJ, et al. Interictal burden attributable to episodic headache: findings from the Eurolight project. J Headache Pain. 2016;17:9. doi:10.1186/s10194-016-0599-8
   PubMed Web of Science ®Google Scholar
• Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;15(372):307–315. doi:10.1016/j.jns.2016.11.071
   Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Katsarava Z, et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 2014;15(1):31. doi:10.1186/1129-2377-15-31
   PubMed Web of Science ®Google Scholar
• Raggi A, Covelli V, Leonardi M, Grazzi L, Curone M, D’Amico D. Difficulties in work-related activities among migraineurs are scarcely collected: results from a literature review. Neurol Sci. 2014;35(Suppl 1):23–26. doi:10.1007/s10072-014-1736-2
   Web of Science ®Google Scholar
• Rencz F, Brodszky V, Péntek M, Bereczki D, Gulácsi L. Health state utilities for migraine based on attack frequency: a time trade-off study. Neurol Sci. 2015;36(2):197–202. doi:10.1007/s10072-014-1920-4
   Web of Science ®Google Scholar
• Buse DC, Lipton RB, Hallström Y, et al. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia. 2018;38(10):1622–1631. doi:10.1177/0333102418789072
   PubMed Web of Science ®Google Scholar
• Smitherman TA. Nonpharmacologic treatment of migraine. In: Smitherman TA, editor. Clinician’s Manual on Migraine. Adis: Cham; 2016:69–77.
   Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470–485. doi:10.1177/0333102416678382
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second International Burden of Migraine Study (IBMS-II). Headache. 2013;53(4):644–655. doi:10.1111/head.12055
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006;26(9):1168–1170. doi:10.1111/j.1468-2982.2006.01173.x
   Web of Science ®Google Scholar
• Silberstein SD. Practice parameter – evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology for the United States Headache Consortium. Neurology. 2000;55(6):754–762. doi:10.1212/WNL.55.6.754
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalagia. 2015;35(6):478–488. doi:10.1177/0333102414547138
   PubMed Web of Science ®Google Scholar
• Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422–435. doi:10.1016/S0025-6196(11)60561-2
   PubMed Web of Science ®Google Scholar
• Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19(1):115. doi:10.1186/s10194-018-0946-z
   PubMed Web of Science ®Google Scholar
• Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand. Curr Med Res Opin. 2008;24(11):3063–3072. doi:10.1185/03007990802457040
   PubMed Web of Science ®Google Scholar
• Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371–380. doi:10.2147/DMSO.S120101
   PubMed Web of Science ®Google Scholar
• Babineaux SM, Curtis B, Holbrook T, et al. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6:e010352. doi:10.1136/bmjopen-2015-010352
   PubMed Web of Science ®Google Scholar
• Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache. 1998;38(4):295–302. doi:10.1046/j.1526-4610.1998.3804295.x
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19(2):107–114. doi:10.1046/j.1468-2982.1999.019002107.x
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20–S28. doi:10.1212/WNL.56.suppl_1.S20
   PubMed Web of Science ®Google Scholar
• The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208. doi:10.1016/0168-8510(90)90421-9
   PubMed Web of Science ®Google Scholar
• Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72. doi:10.1016/0168-8510(96)00822-6
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365. doi:10.2165/00019053-199304050-00006
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Position statement on use of the EQ-5D-5L valuation set for England; 2019. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l. AccessedJune 15, 2021.
   Google Scholar
• van Reenan M, Janssen B. EQ-5D-5L user guide. Basic information on how to use the EQ-5D-5L instrument; 2019. Available from: https://euroqol.org/wp-content/uploads/2021/01/EQ-5D-5LUserguide-08-0421.pdf. Accessed June 15, 2021.
   Google Scholar
• Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D; 2014. Available from: https://link.springer.com/content/pdf/10.1007/978-94-007-7596-1.pdf. Accessed June 15, 2021.
   Google Scholar
• Scher AI, Buse DC, Fanning KM, et al. Comorbid pain and migraine chronicity: the chronic migraine epidemiology and outcomes study. Neurology. 2017;89(5):461–468. doi:10.1212/WNL.0000000000004177
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Martelletti P, et al. Impact of migraine on fibromyalgia symptoms. J Headache Pain. 2016;17:28. doi:10.1186/s10194-016-0619-8
   Web of Science ®Google Scholar
• Affaitati G, Costantini R, Tana C, Cipollone F, Giamberardino MA. Co-occurrence of pain syndromes. J Neural Transm (Vienna). 2020;127(4):625–646. doi:10.1007/s00702-019-02107-8
   PubMed Web of Science ®Google Scholar
• Pike J, Mutebi A, Shah N, et al. Factors associated with a history of failure and switching migraine prophylaxis treatment: an analysis of clinical practice data from the United States, Germany, France, and Japan. Value Health. 2016;19:A68 (abstr PND52). doi:10.1016/j.jval.2016.03.213
   Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6. doi:10.1186/s10194-018-0955-y
   Web of Science ®Google Scholar
• American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.
   PubMed Web of Science ®Google Scholar
• Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M. Quality of life in primary headache disorders: a review. Cephalalgia. 2016;36(1):67–91. doi:10.1177/0333102415580099
   PubMed Web of Science ®Google Scholar
• Raub A, Chung P, Batra P, et al. Paid leave for personal illness: a detailed look at approaches across OECD countries; 2018. Available from https://www.worldpolicycenter.org/sites/default/files/WORLD%20Report%20-%20Personal%20Medical%20Leave%20OECD%20Country%20Approaches_0.pdf. Accessed June 15, 2021.
   Google Scholar
• Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S. Patients’ perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain. 2018;19(1):82. doi:10.1186/s10194-018-0907-6
   PubMed Web of Science ®Google Scholar
• Shah N, Pike J, Mutebi A, et al. The use of migraine prophylaxis treatments in the United States of America: analysis of data from clinical practice. Headache. 2016;56(Suppl1):abstr PS45.
   Google Scholar
• Shah N, Pike J, Mutebi A, et al. Characterizing patient-reported health-related quality of life measures among users and non-users of migraine prophylaxis treatment: an analysis of clinical practice data from the United States, Germany, France, and Japan. Value Health. 2016;19:A68 (poster PND53). doi:10.1016/j.jval.2016.03.214
   Web of Science ®Google Scholar
• Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ. Poor medical care for people with migraine in Europe – evidence from the Eurolight study. J Headache Pain. 2018;27(9):1000–1004.
   Google Scholar
• Dodick DW, Loder EW, Manack Adams A, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2016;56(5):821–834. doi:10.1111/head.12774
   PubMed Web of Science ®Google Scholar